Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Carvykti | Vintage Vibes

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded. Chief Executive Officer Ying Huang said the company beg

MarketBeat · May 12

Legend Biotech Shares Move Higher After Bullish BMO Pitch

Legend Biotech Shares Move Higher After Bullish BMO Pitch

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy Though the analyst expects a gradual increase in sales due…

Benzinga · Jun 17, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

BMO Capital Markets

NonHodgkin lymphoma

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

420,308 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play